Physician profile
Vikas Singh
NPI 1346635539
$6,429.33
in general payments reported to CMS, 2019-2025
27 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $1,484 · 2023: $1,555 · 2024: $1,197 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,344.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $974.30 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals Lp | $849.18 | 2021-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $557.87 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $484.83 | 2021-2025 | |
| Travere Therapeutics, INC. | $434.70 | 2022-2025 | |
| Horizon Therapeutics Plc | $398.91 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $354.35 | 2021-2025 | Jynarque |
| Glaxosmithkline, LLC. | $322.46 | 2021-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $281.37 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $268.83 | 2021-2025 | Acthar |
| Vifor Pharma, INC. | $208.59 | 2021-2024 | Veltassa |
| Novo Nordisk INC | $207.55 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $183.39 | 2021-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $170.46 | 2022-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $147.97 | 2022-2025 | Velphoro, Korsuva, Velphoro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $103.92 | 2021-2023 | Ultomiris |
| Daiichi Sankyo INC. | $92.91 | 2021-2023 | Injectafer |
| Ardelyx, INC. | $72.03 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $65.59 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.82 | 2022-2025 | Jardiance |
| Scpharmaceuticals INC. | $43.35 | 2025 | |
| Lilly USA, LLC | $37.16 | 2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $32.54 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.63 | 2023 | Givlaari |
| Kyowa Kirin, INC. | $21.01 | 2023 | |
| Akebia Therapeutics INC | $19.17 | 2021 | |
| Recor Medical INC | $16.44 | 2025 | Paradise Ultrasound Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.